Hemenway Trust Hemenway Trust’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Hemenway Trust Hemenway Trust’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-10,480	Closed	-$32K	–	133
2019 Q4	$32K	Buy	+10,480	New	+$27.3K	﹤0.01%	132

Other funds holding BMY.RT

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Hemenway Trust Hemenway Trust's BMY.RT Position: Q1 2020 in Review

Hemenway Trust Hemenway Trust sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2020, closing a stake of 10,480 shares — an estimated $32K sold.

Hemenway Trust Hemenway Trust first reported a position in BMY.RT in Q4 2019 and held it in 1 quarter. The position peaked at $32K in Q4 2019. 581 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2020.

Hemenway Trust Hemenway Trust reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2020 after selling out during the quarter.
Hemenway Trust Hemenway Trust sold 10,480 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2020, an estimated $32K.
Hemenway Trust Hemenway Trust first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 1 quarter.
Hemenway Trust Hemenway Trust's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $32K in Q4 2019.
581 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2020.

Based on Hemenway Trust Hemenway Trust's 13F filing for Q1 2020, filed 7 May 2020.